Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $438000.0.

  • Cartesian Therapeutics' Other Working Capital Changes changed N/A to $438000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 16848.91%. This contributed to the annual value of -$5.8 million for FY2024, which is 21128.23% down from last year.
  • As of Q3 2025, Cartesian Therapeutics' Other Working Capital Changes stood at $438000.0.
  • Cartesian Therapeutics' Other Working Capital Changes' 5-year high stood at $9.2 million during Q1 2023, with a 5-year trough of -$26.9 million in Q1 2022.
  • Over the past 5 years, Cartesian Therapeutics' median Other Working Capital Changes value was -$2.7 million (recorded in 2021), while the average stood at -$6.2 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 457213.11% in 2021, then soared by 20722.83% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Other Working Capital Changes (Quarter) stood at -$17.1 million in 2021, then surged by 49.26% to -$8.7 million in 2022, then surged by 73.77% to -$2.3 million in 2023, then surged by 81.87% to -$412000.0 in 2024, then soared by 206.31% to $438000.0 in 2025.
  • Its last three reported values are $438000.0 in Q3 2025, -$706000.0 for Q2 2025, and $5.8 million during Q1 2025.